A prospective, multi-center investigational study of IMMrayTM PanCan-d diagnostic platform for early detection of pancreatic ductal adenocarcinoma in high-risk populations (PANFAM-1 Study)
This is an international, multi-center study with the purpose of assessing the natural occurrence of pancreatic cancer in high risk groups and to test a pancreatic cancer screening test, called "IMMray," which is a new pancreatic cancer biomarker test that looks for signs in the blood that might indicate the presence of pancreatic cancer. Participants will undergo blood collection every six months, and the results from the samples will be correlated with annual imaging of the pancreas either through MRI, CT scan, or endoscopic ultrasound. Learn more
Preliminary Evaluation of Screening for Pancreatic Cancer in Patients with Inherited Genetic Risk
This study is a prospective, observational, case-control study evaluating the utility of endoscopic ultrasound or MRI for the identification of pre-neoplastic and neoplastic pancreatic lesions in patients at high risk for pancreatic cancer, specifically those with BRCA1, BRCA2, PALB2, and ATM mutations.
The Cancer of the Pancreas Screening-5 (CAPS5) Study
This is a multi-center study with the goal of determining the prevalence of pancreatic lesions, pancreatic fluid mutations and circulating pancreatic epithelial cells among a large cohort of high-risk individuals undergoing pancreatic screening and surveillance. Eligible patients include those with a strong family history of pancreatic cancer on one side of their family, Peutz-Jeghers syndrome, or a confirmed germline mutation in a gene that is known to increase the risk of pancreatic cancer development (BRCA1/2, FAMMM [p16/CDKN2A], PALB2, ATM, Lynch syndrome [MLH1, MSH2, MSH6, PMS1, EPCAM], or hereditary pancreatitis [PRSS1/2 or CTRC]). Participants will undergo annual monitoring of the pancreas, primarily through the use of endoscopic ultrasound. Learn more
Pancreatic Cancer Early Detection (PRECEDE) Consortium
The purpose of the PancReatic Cancer Early DEtection (PRECEDE) Consortium is to conduct research on multiple aspects of early detection and prevention of pancreatic cancer. This will be done by establishing a multi-site cohort of individuals with a strong family history of pancreatic cancer and/or individuals carrying mutations in genes linked to pancreatic cancer risk for longitudinal follow up. Enrollment in this study does not preclude enrollment in other pancreatic cancer early detection studies. The PRECEDE consortium is sponsored by Project Purple. Learn more
View the full list of clinical trials
Every day, we work to better understand, diagnose and treat hereditary gastrointestinal cancer and polyposis syndromes. One way that we're doing this at Penn Medicine is through the Gastrointestinal Cancer and Polyposis Registry. The Gastrointestinal Cancer and Polyposis Registry is a voluntary research registry for patients, which facilitates research on gastrointestinal cancer and polyposis syndromes. Patient participation in this registry enables our clinical staff to store medical and family history information, and allows us to contact participants in the future if we have updated information on testing results, new testing options or advances related to a condition, research opportunities, clinical trials or new therapies.
Learn more about the Gastrointestinal Cancer and Polyposis Registry by downloading our guide and consent form.